Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study

Donghao Zhou, Bo Xi, Min Zhao, Liang Wang, Sreenivas P Veeranki, Donghao Zhou, Bo Xi, Min Zhao, Liang Wang, Sreenivas P Veeranki

Abstract

Clinical trials had provided evidence for the benefit effect of antihypertensive treatments in preventing future cardiovascular disease (CVD) events; however, the association between hypertension, whether treated/untreated or controlled/uncontrolled and risk of mortality in US population has been poorly understood. A total of 13,947 US adults aged ≥18 years enrolled in the Third National Health and Nutrition Examination Survey (1988-1994) were used to conduct this study. Mortality outcome events included all-cause, CVD-specific, heart disease-specific and cerebrovascular disease-specific deaths, which were obtained from linked 2011 National Death Index (NDI) files. During a median follow-up of 19.1 years, there were 3,550 all-cause deaths, including 1,027 CVD deaths. Compared with normotensives, treated but uncontrolled hypertensive patients were at higher risk of all-cause (HR = 1.62, 95%CI = 1.35-1.95), CVD-specific (HR = 2.23, 95%CI = 1.66-2.99), heart disease-specific (HR = 2.19, 95%CI = 1.57-3.05) and cerebrovascular disease-specific (HR = 3.01, 95%CI = 1.91-4.73) mortality. Additionally, untreated hypertensive patients had increased risk of all-cause (HR = 1.40, 95%CI = 1.21-1.62), CVD-specific (HR = 1.77, 95%CI = 1.34-2.35), heart disease-specific (HR = 1.69, 95%CI = 1.23-2.32) and cerebrovascular disease-specific death (HR = 2.53, 95%CI = 1.52-4.23). No significant differences were identified between normotensives, and treated and controlled hypertensives (all p > 0.05). Our study findings emphasize the benefit of secondary prevention in hypertensive patients and primary prevention in general population to prevent risk of mortality later in life.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan-Meier survival estimates for (A) all-cause mortality, (B) CVD-specific mortality, (C) heart disease-specific mortality, and (D) cerebrovascular disease-specific mortality among four study exposure groups.

References

    1. Writing Group M, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38–360. doi: 10.1161/CIR.0000000000000350.
    1. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518. doi: 10.1016/S0140-6736(08)60655-8.
    1. James PA, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311:507–520. doi: 10.1001/jama.2013.284427.
    1. Gueyffier F, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761–767. doi: 10.7326/0003-4819-126-10-199705150-00002.
    1. Thurmer HL, Lund-Larsen PG, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens. 1994;12:481–490.
    1. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907–913. doi: 10.1161/01.HYP.0000165020.14745.79.
    1. Benetos A, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577–581. doi: 10.1001/archinte.162.5.577.
    1. Barengo NC, Kastarinen M, Antikainen R, Nissinen A, Tuomilehto J. The effects of awareness, treatment and control of hypertension on cardiovascular and all-cause mortality in a community-based population. J Hum Hypertens. 2009;23:808–816. doi: 10.1038/jhh.2009.30.
    1. da Silva TL, Klein CH, Nogueira Ada R, Salis LH. de Souza ESNA, Bloch KV. Cardiovascular mortality among a cohort of hypertensive and normotensives in Rio de Janeiro - Brazil - 1991–2009. BMC Public Health. 2015;15:623. doi: 10.1186/s12889-015-1999-4.
    1. Lotfaliany M, et al. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a Middle East cohort. J Hypertens. 2015;33:1153–1161. doi: 10.1097/HJH.0000000000000540.
    1. Kelly TN, et al. Hypertension subtype and risk of cardiovascular disease in Chinese adults. Circulation. 2008;118:1558–1566. doi: 10.1161/CIRCULATIONAHA.107.723593.
    1. Barengo NC, Antikainen R, Kastarinen M, Laatikainen T, Tuomilehto J. The effects of control of systolic and diastolic hypertension on cardiovascular and all-cause mortality in a community-based population cohort. J Hum Hypertens. 2013;27:693–697. doi: 10.1038/jhh.2013.22.
    1. Kronish IM, et al. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2016;68:39–45. doi: 10.1161/HYPERTENSIONAHA.115.06960.
    1. Diaz KM, et al. Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension. 2014;64:965–982. doi: 10.1161/HYPERTENSIONAHA.114.03903.
    1. Mazzaglia G, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–1605. doi: 10.1161/CIRCULATIONAHA.108.830299.
    1. Townsend RR, Epstein M. Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era. Hypertension. 2016;68:1073–1080. doi: 10.1161/HYPERTENSIONAHA.116.07316.
    1. Fang J, Yang Q, Ayala C, Loustalot F. Disparities in access to care among US adults with self-reported hypertension. Am J Hypertens. 2014;27:1377–1386. doi: 10.1093/ajh/hpu061.
    1. Lanti M, et al. Antihypertensive treatment is not a risk factor for major cardiovascular events in the Gubbio residential cohort study. J Hypertens. 2015;33:736–744. doi: 10.1097/HJH.0000000000000490.
    1. Mills KT, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134:441–450. doi: 10.1161/CIRCULATIONAHA.115.018912.
    1. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130:1692–1699. doi: 10.1161/CIRCULATIONAHA.114.010676.
    1. Krakoff LR, et al. 2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. J Am Coll Cardiol. 2014;64:394–402. doi: 10.1016/j.jacc.2014.06.014.
    1. Pflederer MC, Estacio RO, Krantz MJ. Is 60 the New 80 in Hypertension? J Gen Intern Med. 2016;31:958–960. doi: 10.1007/s11606-016-3649-7.
    1. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8.
    1. Xie X, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443. doi: 10.1016/S0140-6736(15)00805-3.
    1. Williamson JD, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial. JAMA. 2016;315:2673–2682. doi: 10.1001/jama.2016.7050.
    1. Centers for Disease Control and Prevention. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat 1, 1–407 (1994).
    1. National Center for Health Statistics. Office of Analysis and Epidemiology, NCHS 2011 Linked Mortality Files Matching Methodology, (Accessed May 1, 2018).

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir